FDA OKs label update
[ad_1]
This label change reassuringly supports standard clinical practice: less than monthly dosing of Lucentis, often in a treat-and-extend approach to wet AMD.
San Francisco—The FDA has approved a new label update tied to Genentech’s ranibizumab (Lucentis) prescribing information for wet age-related macular degeneration (AMD). The re
[ad_2]
Return to main website.